AU2005215376B2 - Dopamine-agonist combination therapy with sedatives for improving sleep quality - Google Patents

Dopamine-agonist combination therapy with sedatives for improving sleep quality Download PDF

Info

Publication number
AU2005215376B2
AU2005215376B2 AU2005215376A AU2005215376A AU2005215376B2 AU 2005215376 B2 AU2005215376 B2 AU 2005215376B2 AU 2005215376 A AU2005215376 A AU 2005215376A AU 2005215376 A AU2005215376 A AU 2005215376A AU 2005215376 B2 AU2005215376 B2 AU 2005215376B2
Authority
AU
Australia
Prior art keywords
optically pure
dopamine
pharmaceutically acceptable
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005215376A
Other languages
English (en)
Other versions
AU2005215376A1 (en
Inventor
Timothy J. Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of AU2005215376A1 publication Critical patent/AU2005215376A1/en
Assigned to SEPRACOR INC. reassignment SEPRACOR INC. Request for Assignment Assignors: SEPRACOR, INC.
Application granted granted Critical
Publication of AU2005215376B2 publication Critical patent/AU2005215376B2/en
Priority to AU2011201703A priority Critical patent/AU2011201703A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005215376A 2004-02-18 2005-02-07 Dopamine-agonist combination therapy with sedatives for improving sleep quality Ceased AU2005215376B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011201703A AU2011201703A1 (en) 2004-02-18 2011-04-15 Dopamine-agonist combination therapy for improving sleep quality

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54541304P 2004-02-18 2004-02-18
US60/545,413 2004-02-18
PCT/US2005/003937 WO2005079851A2 (en) 2004-02-18 2005-02-07 Dopamine-agonist combination therapy with sedatives for improving sleep quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011201703A Division AU2011201703A1 (en) 2004-02-18 2011-04-15 Dopamine-agonist combination therapy for improving sleep quality

Publications (2)

Publication Number Publication Date
AU2005215376A1 AU2005215376A1 (en) 2005-09-01
AU2005215376B2 true AU2005215376B2 (en) 2011-01-20

Family

ID=34886149

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005215376A Ceased AU2005215376B2 (en) 2004-02-18 2005-02-07 Dopamine-agonist combination therapy with sedatives for improving sleep quality
AU2011201703A Abandoned AU2011201703A1 (en) 2004-02-18 2011-04-15 Dopamine-agonist combination therapy for improving sleep quality

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011201703A Abandoned AU2011201703A1 (en) 2004-02-18 2011-04-15 Dopamine-agonist combination therapy for improving sleep quality

Country Status (10)

Country Link
US (2) US20050267176A1 (https=)
EP (1) EP1742624B1 (https=)
JP (1) JP2007523165A (https=)
AT (1) ATE454140T1 (https=)
AU (2) AU2005215376B2 (https=)
CA (1) CA2556870C (https=)
DE (1) DE602005018763D1 (https=)
DK (1) DK1742624T3 (https=)
ES (1) ES2337700T3 (https=)
WO (1) WO2005079851A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
EP1732559B1 (en) 2004-04-05 2017-03-22 Sunovion Pharmaceuticals Inc. Methods of treatment using eszopiclone
EP1844047A1 (en) * 2004-10-18 2007-10-17 Neurocrine Biosciences, Inc. Hydrate of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]- pyramidin-7-yl}phenyl)acetamide and processes and methods related thereto
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EP2455075B1 (en) 2005-07-06 2018-06-20 Sunovion Pharmaceuticals Inc. Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
US20070270590A1 (en) * 2006-04-20 2007-11-22 Marioara Mendelovici Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
US20080045547A1 (en) * 2006-07-07 2008-02-21 Lippa Arnold S Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US20080299189A1 (en) * 2007-06-04 2008-12-04 Drugtech Corporation Controlled release dopamine agonist compositions
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
MX2011004769A (es) * 2008-11-06 2011-11-29 Biotie Therapies Inc Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño.
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
US20100221338A1 (en) * 2009-01-30 2010-09-02 Sepracor Inc. Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of Coating
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
MX2012012069A (es) 2010-04-30 2012-11-22 Teikoku Pharma Usa Inc Composiciones transdermicas de propinilaminoindan.
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP3334427A4 (en) * 2015-08-11 2019-02-06 Ovid Therapeutics, Inc. METHOD OF SUSPENSION AND PARENTERAL FORMULATION FOR USE IN INTENSIVE TREATMENT
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
EP3506906A4 (en) 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
NZ781774A (en) 2019-03-08 2023-03-31 Taro Pharma Ind Stable topical compositions of fenoldopam
BR112021021260A2 (pt) * 2019-04-22 2022-02-08 L Knobler Robert Tratamento não hormonal de ondas de calor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US20020143016A1 (en) * 1999-05-14 2002-10-03 Sepracor, Inc. Methods of treating muscle spasms using N-desmethylzopiclone
WO2003022259A1 (en) * 2001-09-13 2003-03-20 Sepracor Inc. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US4505029A (en) * 1981-03-23 1985-03-19 General Electric Company Semiconductor device with built-up low resistance contact
US4419345A (en) * 1981-07-20 1983-12-06 Kinetic Systems, Inc. Sleep-inducing pharmaceutical composition and method
DE3228351C2 (de) * 1982-07-29 1985-07-25 Merckle GmbH, 7902 Blaubeuren Arzneimittel zur Behandlung von Schlafstörungen
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4654347A (en) 1983-06-23 1987-03-31 American Cyanamid Company Aryl and heteroaryl[[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
FR2606410B1 (fr) 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
US5017616A (en) * 1989-11-30 1991-05-21 Jeffrey Askanazi Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US5538977A (en) 1995-03-17 1996-07-23 American Cyanamid Company 3-Substituted-7-[3-(imidazol-1-yl)phenyl]-pyrazolo[1,5-a]pyrimidines
IT1276522B1 (it) 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US5714607A (en) 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
US6211173B1 (en) * 1997-03-12 2001-04-03 Cenes Limited Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
EP1169029B1 (en) * 1999-03-19 2005-05-04 Abbott GmbH & Co. KG Use of sibutramine or its derivative for the treatment of sleep disorders
US6231594B1 (en) * 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
WO2004037212A2 (en) * 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
DK1641456T3 (da) 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
CA2551637A1 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
WO2005072715A1 (en) * 2004-01-29 2005-08-11 Sepracor Inc. Use of (s)-didesmethylsibutraminefor treating, preventing and managing a sleep disorder
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
EP1732559B1 (en) 2004-04-05 2017-03-22 Sunovion Pharmaceuticals Inc. Methods of treatment using eszopiclone
US7465729B2 (en) 2004-04-05 2008-12-16 Sepracor Inc. Methods of treatment of menopause and perimenopause using eszopiclone
WO2007005940A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
CA2614209A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
CN101257907A (zh) 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
EP2455075B1 (en) 2005-07-06 2018-06-20 Sunovion Pharmaceuticals Inc. Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US6436936B1 (en) * 1991-12-02 2002-08-20 Sepracor Inc. Methods and compositions for treating disorders, using optically pure (+) zopiclone
US20020143016A1 (en) * 1999-05-14 2002-10-03 Sepracor, Inc. Methods of treating muscle spasms using N-desmethylzopiclone
WO2003022259A1 (en) * 2001-09-13 2003-03-20 Sepracor Inc. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites

Also Published As

Publication number Publication date
DE602005018763D1 (de) 2010-02-25
JP2007523165A (ja) 2007-08-16
EP1742624B1 (en) 2010-01-06
AU2005215376A1 (en) 2005-09-01
EP1742624A2 (en) 2007-01-17
US20100004251A1 (en) 2010-01-07
WO2005079851A2 (en) 2005-09-01
CA2556870A1 (en) 2005-09-01
AU2011201703A1 (en) 2011-05-12
US8877755B2 (en) 2014-11-04
CA2556870C (en) 2014-01-28
US20050267176A1 (en) 2005-12-01
ATE454140T1 (de) 2010-01-15
ES2337700T3 (es) 2010-04-28
WO2005079851A3 (en) 2006-06-22
DK1742624T3 (da) 2010-03-08

Similar Documents

Publication Publication Date Title
AU2005215376B2 (en) Dopamine-agonist combination therapy with sedatives for improving sleep quality
CA2548917C (en) Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050164987A1 (en) Melatonin combination therapy for improving sleep quality
US20050215521A1 (en) Modafinil combination therapy for improving sleep quality
CA2450787C (en) Active ingredient combination for pharmacological addictive substance or intoxicant therapy
US20220160711A1 (en) Methods of treating or preventing preterm labor
HK1095279B (en) Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
MX2008016225A (es) Preparaciones de combinacion que comprenden slv308 y l-dopa.

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SEPRACOR INC.

Free format text: FORMER NAME: SEPRACOR, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired